Dr. Aslam Ejaz, M.D.
Surgical Oncology (Surgical Oncology Physician)
1740 W Taylor St
Chicago, IL 60612
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Howard University College of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 20
Licensed in Illinois since 2013, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Howard University College of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Surgical Oncology Physician primary
IL license 036133247 (first issued 2013; active) -
Surgery Physician
IL license 036133247 (first issued 2013; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Illinois Hospital and Clinics Chicago, IL
- John H Stroger Jr Hospital Chicago, IL
Medical groups
- The Board of Trustees of the University of Illinois (1,150 clinicians)
- Cook County (788 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 20
- Services billed
- 65
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 93 | 61 |
| New patient office or other outpatient visit, 60-74 minutes | 34 | 34 |
| Telephone medical discussion with physician, 21-30 minutes | 33 | 25 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 17 payments worth $14,021 in total to this clinician.
| Dilon Technologies, Inc. | $13,789 |
|---|---|
| Medtronic, Inc. | $202 |
| Beigene USA, Inc. | $29.84 |
| Consulting Fee | $12,500 |
|---|---|
| Food and Beverage | $1,521 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Dilon Technologies, Inc. Jan 3, 2025 | Consulting Fee HEMOBLAST BELLOWS · HEMOSTATIC AGENT | $2,500 |
| Dilon Technologies, Inc. Mar 7, 2025 | Consulting Fee HEMOBLAST BELLOWS · HEMOSTATIC AGENT | $2,500 |
| Dilon Technologies, Inc. May 9, 2025 | Consulting Fee HEMOBLAST BELLOWS · HEMOSTATIC AGENT | $2,500 |
| Dilon Technologies, Inc. Jul 25, 2025 | Consulting Fee HEMOBLAST BELLOWS · HEMOSTATIC AGENT | $2,500 |
| Dilon Technologies, Inc. Nov 14, 2025 | Consulting Fee HEMOBLAST BELLOWS · HEMOSTATIC AGENT | $2,500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $148,614 in research payments for these studies, mostly to the institutions running them.
- An Open-Label Expanded Access Study of the Melphalan/?Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Delcath Systems
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.